South Korean pharmaceutical and bio companies are expanding into the materials business. The move is seen as a strategy to secure stable revenue streams amid anticipated policy changes such as drug price cuts and the inherently long timelines required for new drug development. Some companies are already generating visible sales from electronic materials businesses, translating into higher corporate valuations.
